An investigation for investors in Neos Therapeutics Inc (NASDAQ:NEOS) shares over potential securities laws violations by Neos Therapeutics was announced and NASDAQ:NEOS stockholders should contact the Shareholders Foundation.
San Diego, CA -- (SBWIRE) -- 11/09/2015 -- An investigation for shareholders in NASDAQ:NEOS shares over potential securities laws violations by Neos Therapeutics in connection certain financial statements was announced.
Investors who purchased shares of Neos Therapeutics Inc (NASDAQ:NEOS), have certain options and should contact the Shareholders Foundation at email@example.com or call 858-779-1554.
The investigation by a law firm focuses on whether certain statements by Neos Therapeutics regarding its business, its prospects and its operations were materially false and misleading at the time they were made.
On October 19, 2015 Neos Therapeutics Inc announced that, on October 16, 2015, the Company received a notification from the U.S. Food and Drug Administration ('FDA') stating that, as part of its ongoing review of the Company's New Drug Application ('NDA') for Cotempla XR-ODT (Methylphenidate Extended Release Orally Disintegrating) 10 mg, 20mg, and 30 mg tablets, it has identified deficiencies that preclude discussion of labeling and postmarketing requirements/commitments at this time. Shares of Neos Therapeutics Inc (NASDAQ:NEOS) declined to as low as $11.53 per share on October 22, 2015.
On November 6, 2015, NASDAQ:NEOS shares closed at $13.64 per share.
Those who purchased shares of Neos Therapeutics Inc (NASDAQ:NEOS) have certain options and should contact the Shareholders Foundation.
Shareholders Foundation, Inc.
3111 Camino Del Rio North - Suite 423
92108 San Diego